• HyperScribe T7 High Yield Cy5 RNA Labeling Kit

  2026-09-13

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit is a 25-reaction system for T7-mediated in vitro transcription of fluorescent RNA probes. Its Cy5-UTP substitution can be optimized to balance RNA yield and labeling intensity, supporting in situ hybridization and Northern blot hybridization workflows.

• Olaparib in Spliceosome-Driven Cancer Research

  2026-09-12

  Olaparib (AZD2281) connects PARP inhibition with practical studies of homologous recombination loss, spliceosome disruption, and tumor radiosensitization. This workflow-focused guide explains how to design DNA damage response assays, interpret combination effects, and troubleshoot exposure, controls, and endpoint selection.

• Risedronate Sodium Microneedles for Osteoporosis

  2026-09-11

  The reference study developed a dissolving gelatin microneedle patch containing Risedronate Sodium and ursolic acid within optimized bipartite nanotransfersomes. Its formulation showed high drug entrapment, sustained release, uniform patch content, and substantial ex vivo skin permeation, supporting further investigation of transdermal delivery for osteoporosis rather than demonstrating clinical efficacy.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-09-11

  Protect protein abundance and phosphorylation during cell, tissue, and organoid lysis with an EDTA-free 100X formulation. This workflow connects practical sample handling to PTGER4–HDAC signaling studies, where preserving phosphoproteins can determine whether a mechanistic result is visible.

• HyperScribe SP6 High Yield RNA Synthesis Kit Workflow

  2026-09-10

  Build high-yield, sequence-defined RNA for probe, translation, RNAi, and innate-immunity assays with a flexible SP6 transcription workflow. The HyperScribe™ platform combines substantial output with options for capped, dye-labeled, biotinylated, and radiolabeled RNA formats.

• Dual HER2/VEGFR2 Targeting in TNBC

  2026-09-10

  The 2026 reference study examines whether combined HER-2 and VEGFR-2 tyrosine kinase inhibition can suppress migration-associated phenotypes in the HER2-negative TNBC model MDA-MB-231. Lapatinib and Telatinib reduced proliferation, invadopodia formation, and 2D angiogenic tube formation, providing a phenotype-focused rationale for further targeted cancer therapy research while leaving target-specific mechanisms to be resolved.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Protocol Guide

  2026-09-09

  SKU K1223 provides an affinity-purified, HRP-labeled reagent for detecting rabbit IgG primary antibodies in Western blot, ELISA, IHC, and immunocytochemistry workflows. It is intended for research use only and should not be used for diagnostic, medical, or unvalidated live-cell sorting applications.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding

  2026-09-09

  Oliveira and colleagues show that naturally occurring angiotensin fragments differentially enhance SARS-CoV-2 spike binding to AXL, ACE2, and neuropilin-1, with shorter N-terminal deletion products showing particularly strong activity. The antibody-based binding study links renin–angiotensin system peptide processing to a potential viral-entry mechanism, while its in vitro design underscores the need for infection and in vivo validation.

• Angiotensin 1/2 (5-7): From RAS to Translation

  2026-09-08

  A thought-leadership guide to using Angiotensin 1/2 (5-7) as a mechanistic probe in renin-angiotensin system research, hypertension models, and emerging SARS-CoV-2 spike-binding studies.

• 7ACC2 and the Metabolic Logic of Tumor Immunity

  2026-09-08

  7ACC2 is a potent monocarboxylate transporter 1 inhibitor that also disrupts mitochondrial pyruvate transport. This thought-leadership article examines how its dual metabolic activity can strengthen cancer metabolism research, guide translational assay design, and open a carefully bounded path toward studying tumor–immune metabolic crosstalk.

• P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL

  2026-09-07

  Li et al. connect P2RX1 activity with calcium imbalance, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. The work provides a mechanistic framework for studying tyrosine kinase inhibitor responses while highlighting the need for validation beyond a single engineered cell-line model.

• Ferroptosis Signature Identifies Atorvastatin in HCC

  2026-09-07

  A 2025 study integrates ferroptosis-related transcriptomics, clinical survival data, and Connectivity Map screening to develop a four-gene prognostic signature for hepatocellular carcinoma (HCC). It further identifies Atorvastatin as a candidate compound and reports that the drug suppresses HCC growth and migration while inducing ferroptosis in cellular and animal models.

• Naftifine HCl: Applied Antifungal Workflows

  2026-09-05

  Build reproducible fungal growth, membrane-phenotype, and selectivity assays around Naftifine HCl without confusing research workflows with clinical use. This guide combines solvent-control strategy, orthogonal readouts, and pathway-aware experimental design inspired by muscle progenitor research.

• Caspase-3/7 Inhibitor I: Mechanism & Use

  2026-09-04

  Caspase-3/7 Inhibitor I is a reversible caspase-7 inhibitor and cell-permeable isatin sulfonamide that preferentially inhibits caspase-3 and caspase-7. Its reported selectivity, cellular benchmarks, and formulation limits make it useful for mechanistic apoptosis studies, including infection and cancer research models.

• FOXO3–YAP Metabolic Targeting in HCC

  2026-09-04

  The reference study identifies FOXO3 as a tumor-suppressive regulator that simultaneously restrains glycolysis and glutaminolysis in hepatocellular carcinoma through direct repression of YAP. Its integrated cell, animal, and patient-derived organoid evidence supports the FOXO3/YAP axis as a mechanistically grounded target for metabolic intervention, while also defining important questions about pathway plasticity and clinical translation.

7842 records 1/523 page Next 12345 下5页 Last page